- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04065633
Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation
A PHASE 1, OPEN LABEL, SINGLE-DOSE, CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE OF A COMMERCIAL TABLET FORMULATION OF PF-04965842 RELATIVE TO THE PHASE III TABLET FORMULATION UNDER FASTING CONDITIONS AND THE EFFECT OF FOOD ON THE RELATIVE BIOAVAILABILITY OF THE COMMERCIAL TABLET FORMULATION IN HEALTHY PARTICIPANTS
Part A
- To measure and compare the amount of study drug in the blood after a single 200 mg dose of study drug given as the commercial tablet formulation and the Phase 3 tablet formulation under fasting conditions
- To measure and compare the amount of study drug in the blood after a single 200 mg dose given as the variant Phase 3 tablet formulation and the Phase 3 tablet formulation under fasting conditions
- To estimate the effect of food on the amount of study drug in the blood after a single 200 mg dose of the commercial formulation
Part B
• To measure and compare the amount of study drug in the blood after a single 200 mg dose given as the commercial tablet formulation and the Phase 3 tablet formulation under fasting conditions
Parts A & B
To collect samples for genotyping (CYP2C19 and CYP2C9 - enzymes that metabolize [break down] certain medications)
o Genotyping is the collection of a small sample of blood that contains your genes
- To evaluate the safety and tolerability of the study drug after single 200 mg doses of the three different formulations given to healthy participants
- To measure the amount of study drug in the blood after single doses of the different formulations
- To collect exploratory samples for biobanking o Biobanking is the collection and storage of blood samples for possible future testing
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study in healthy participants is to estimate the bioavailability (BA) of the commercial formulation of PF-04965842 and a variant formulation with slower dissolution relative to the Phase 3 formulation, to demonstrate the bioequivalence (BE) of the commercial formulation relative to the Phase 3 formulation, and to estimate the effect of food on the BA of the commercial formulation. This study consists of 2 parts: Part A is to estimate the relative BA (rBA) of single 200 mg doses of the commercial tablet formulation of PF-04965842 and a variant formulation of slower dissolution rate compared to the Phase 3 tablet formulation. The effect of food on the BA of the commercial tablet formulation will also be evaluated. Part B is to establish BE between the Phase 3 and commercial formulations. The study will follow a staged approach as the sample size for BE cannot be determined with currently available information.
Therefore, it is proposed to assess the maximum observed concentration (Cmax) and area under the curve (AUC) ratios between the Phase 3 and commercial formulations as well as the within-participant variability of Cmax and AUC values determined in Part A. Based on the results from Part A, the sample size of Part B will be determined and the decision to proceed to Part B will be made.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- New Haven Clinical Research Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb)
Exclusion Criteria:
Any condition possibly affecting drug absorption (eg, gastrectomy).
- History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis
- Evidence or history of clinically significant dermatological condition (eg, atopic dermatitis or psoriasis) .History of tuberculosis (TB) (active or latent) or inadequately treated TB infection.
- History of chronic infections, history of recurrent infections, history of latent infections, .History of disseminated herpes zoster, or disseminated herpes simplex, or recurrent localized dermatomal herpes zoster.
- history of malignancies with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin, or cervical carcinoma in situ
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Part A sequence 1
|
200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions
200 mg PF-04965842 commercial tablet formulation under fasted conditions
200 mg PF-04965842 variant tablet formulation with slower dissolution under fasted conditions
200 mg PF-04965842 commercial tablet formulation under fed conditions
|
EXPERIMENTAL: Part A sequence 2
|
200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions
200 mg PF-04965842 commercial tablet formulation under fasted conditions
200 mg PF-04965842 variant tablet formulation with slower dissolution under fasted conditions
200 mg PF-04965842 commercial tablet formulation under fed conditions
|
EXPERIMENTAL: Part B sequence 1
|
200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions
200 mg PF-04965842 commercial tablet formulation under fasted conditions
|
EXPERIMENTAL: Part B sequence 2
|
200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions
200 mg PF-04965842 commercial tablet formulation under fasted conditions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma PF-04965842 PK parameters
Time Frame: hour 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose
|
AUCinf
|
hour 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose
|
Plasma PF-04965842 PK parameters
Time Frame: hour 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose
|
Cmax
|
hour 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number of subjects with treatment-emergent adverse event
Time Frame: baseline until Period 4 study day 35
|
baseline until Period 4 study day 35
|
|
number of subjects with significant change from baseline in Supine Blood pressure, pulse rate and oral temperature
Time Frame: baseline until Period 4 study day 3
|
The actual and the change from baseline values will be summarized by treatment.
These data will be listed and out of range values will be summarized
|
baseline until Period 4 study day 3
|
number of subjects with significant Changes from baseline for the ECG parameters QT interval, heart rate, QTc interval, PR
Time Frame: baseline until Period 4 study day 3
|
Changes from baseline for the ECG parameters QT interval, heart rate, QTc interval, PR interval, and QRS complex will be summarized by treatment and time.
The number (%) of participants with maximum postdose QTc values and maximum increases from baseline in the following categories will be tabulated by treatment
|
baseline until Period 4 study day 3
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sylvester Pawlak, APRN, Pfizer
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- B7451032
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dermatitis, Atopic
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonNot yet recruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of Scalp
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
Clinical Trials on P3-Fast
-
University of North Carolina, Chapel HillEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedSexually Transmitted Diseases | Adherence, Medication | Safe SexUnited States
-
Duke UniversityChulalongkorn University; Thai Red Cross AIDS Research Centre; University of...CompletedHIV/AIDS | Adherence, Patient | Pre-Exposure ProphylaxisThailand
-
AHS Cancer Control AlbertaRecruiting
-
Florida International UniversityUniversity of Southern California; Universidad Peruana Cayetano HerediaRecruitingHIV Infections | Sexually Transmitted Diseases | Hiv | Sexual Behavior | Risk Reduction | Sexually Transmitted Infections (Not HIV or Hepatitis)United States
-
Centre Hospitalier St AnneRecruitingComatose | Neurophysiologic AbnormalityFrance
-
University of DelawareUniversity of Pennsylvania; Christiana Care Health Services; Indiana UniversityCompleted
-
BIO-CAT, Inc.McGill UniversityCompletedAppetitive Behavior | Gastrointestinal Health | Digestive HealthCanada
-
Aurora Health CareAurora BayCare Medical Center; BayCare Health SystemCompleted